Observe Medical ASA · OSL:OBSRV

Observe Medical ASA — Investor Presentation (June 2020)

24 slides from Observe Medical ASA's investor presentation, Jun 24, 2020

  1. Slide 1: Observe Medical Investor Presentation

    OBSERVE MEDICAL Investor Presentation CEO Björn Larsson / CFO Per Arne Nygård Oslo, June 24, 2020

  2. Slide 2: Copyright and Disclaimer

    Copyright and Disclaimer Copyright Copyright of all published material including photographs, drawings and images in this document remains vested in Observe Medical and third party contributors as appropriate. Accordingly, neither the whole nor any part of this document shall be reproduced in any fo

  3. Slide 3: Disclaimer, cont.

    Disclaimer, cont. Forward-looking statements include statements regarding objectives, goals, strategies, outlook and growth prospects; future plans, events or performance and potential for future growth; liquidity, capital resources and capital expenditures; profit; margin, return on capital, cost o

  4. Slide 4: Disclaimer, cont.

    Disclaimer, cont. and/or Rule 506 of Regulation D promulgated thereunder. Prior to the purchase of any Offer Shares, prospective investors that are U.S. persons or have a registered U.S. address (each a "U.S. Investor") will be required to execute a U.S. Investor Representation Letter to the Manager

  5. Slide 5: Observe Medical Management Team

    PRESENTERS Observe Medical Management Team BJÖRN LARSSON, CHIEF EXECUTIVE OFFICER Broad experience from marketing and business development within medtech, pharmaceuticals and biotech, i.a. from ABIGO Medical, Dentsply, Medtronic, Mentice, AstraZeneca and Novo Nordisk. Email: bjorn.larsson@observemed

  6. Slide 6: Sippi® Overview

    Overview Addressing major challenges: Sippi® Quality assurance of data Solid medtech platform Automated and wireless Stressed out healthcare for growth connected digital urine meter staff for ICUs and wards Hospital acquired infections Strong market opportunity Exploit market Fully underwritten acce

  7. Slide 7: A medtech company with global reach – a platform built for growth

    OBSERVE MEDICAL AT A GLANCE A medtech company with global reach – a platform built for growth Observe Medical is a medtech company with global reach and the competence and experience of bringing medtech products to the market successfully Platform growth both through M&A and organic growth Strong fi

  8. Slide 8: Sippi® - Observe Medical's first product

    OBSERVE MEDICAL AT A GLANCE A medtech company with global reach – a platform built for growth Sippi® - Observe Medical’s first product Observe Medical is a medtech company with global reach and the competence and • Sippi® is a unique, automated and experience of bringing medtech products to wireless

  9. Slide 9: Sippi® - the first automated digital urine meter with biofilm control

    SIPPI® Sippi® - the first automated digital urine meter with biofilm control • Sippi® - the first automated digital urine meter with biofilm control 7

  10. Slide 10: Sippi® addresses major challenges for hospital ICUs

    SIPPI® MARKET OPPORTUNITY Sippi® addresses major challenges for hospital ICUs Challenges Impact Sippi® impact and benefits Urine volume – an important • Suboptimal measurement Automated, digital urine meter parameter monitoring ICU patient accuracy – may lead to the wrong Improved data accuracy and

  11. Slide 11: Advisory Board supports market opportunity and Sippi® relevance

    COMMERCIAL UPDATE Advisory Board supports market opportunity and Sippi® relevance Advisory Board “The COVID-19 pandemic indicated the “Sippi® appears to be highly relevant need for urinary measurement systems from a health economic point of view, that reduces ICU nurse workload, and and it will be v

  12. Slide 12: Research confirms global market potential for Sippi®

    SIPPI® MARKET OPPORTUNITY Observe Medical driven research confirms current global market potential for Sippi® and indicates +100% global market value growth post COVID-19 outbreak Current market Post COVID-19 outbreak market assumptions CURRENT MARKET POTENTIAL ICU CAPABILITIES VOLUME GROWTH SIPPI®

  13. Slide 13: Key focus: Exploit the market potential in the Nordics and Europe

    SIPPI® MARKET OPPORTUNITY Key focus: Exploit the market potential in the Nordics and Europe Estimated up to 3x value growth for Sippi® post COVID-19 outbreak Attractiveness of Nordic and European market Up to 3x market value growth for Sippi® • ICU bed capacity ROW North America • Shortage of hospit

  14. Slide 14: Readiness for commercial execution

    COMMERCIAL UPDATE Readiness for commercial execution Sales Customer prospects delayed, but strong commitment to use Sippi® and to resume implementation Regaining access to customers post acute COVID-19 situation Commercial support Advisory Board with exceptional competence in guiding Sippi® commerci

  15. Slide 15: Fully underwritten rights issue

    THE TRANSACTION Fully underwritten rights issue Offering details Key considerations Issuer Observe Medical ASA Subscription period 19 June – 3 July at 16:30 CET Offer size Rights issue raising gross proceeds of up to NOK 45 million by Subscription rights Each existing shareholder will be granted 0.2

  16. Slide 16: Use of proceeds

    THE TRANSACTION Use of proceeds Net proceeds from rights issue will be used for general corporate purpose with focus on: Go-to-market strategy and execution Clinical and health-economic evidence program • Strengthening the commercial organization within sales, training and • Building additional evid

  17. Slide 17: Summary

    Summary Addressing major challenges: Sippi® Quality assurance of data Solid medtech platform Automated and wireless Stressed out healthcare for growth connected digital urine meter staff for ICUs and wards Hospital acquired infections Strong market opportunity Exploit market Fully underwritten accel

  18. Slide 18: Risk factors

    RISKS RELATED TO THE GROUP AND THE INDUSTRY Risk factors An investment in the Company and the Shares involves inherent risk. Before making an investment decision with respect to the Shares, investors should carefully consider the risk factors and all information contained in this presentation, the R

  19. Slide 19: Risk factors, cont.

    RISKS RELATED TO THE GROUP AND THE INDUSTRY Risk factors, cont. The Group may not obtain the prices it requires for its products The urine measurement market is a mature market dominated by few big suppliers. There is a constant price pressure in this market since it is mainly driven by tenders from

  20. Slide 20: Risk factors, cont.

    RISKS RELATED TO THE GROUP AND THE INDUSTRY Risk factors, cont. The Group's intellectual property rights, including trademarks and trade names, may be infringed, misappropriated or challenged by others; the Group may be subject to liability if it infringes upon the intellectual property rights of th

  21. Slide 21: Risk factors, cont.

    RISKS RELATED TO THE GROUP AND THE INDUSTRY Risk factors, cont. The Group and the industry in which it operates may be adversely affected by global economic market conditions The Group's performance and further development depends on the continued stable growth of the global market for medicine devi

  22. Slide 22: Risk factors, cont.

    RISKS RELATED TO FINANCING AND MARKET RISK Risk factors, cont. There is also the possibility of a breach of the lender's obligations under the Company's existing borrowing arrangement, as the lender is an industrial player and the Company's largest shareholder and not an ordinary financing instituti

  23. Slide 23: Risk factors, cont.

    RISKS RELATED TO FINANCING AND MARKET RISK Risk factors, cont. The Group is exposed to exchange rate fluctuations As a consequence of its international operations, including operations in Sweden and Denmark, administration in Norway, expected sales to the Nordic region and rest of Europe, especially

  24. Slide 24: Risk factors, cont.

    RISKS RELATED TO LAWS, REGULATION AND LITIGATION Risk factors, cont. Whether or not the Group ultimately prevails, litigation and arbitration are costly and can divert Management's attention from the Group's business. In addition, the Group may decide to settle a litigation or arbitration matter, wh

Observe Medical — Investor Presentation (June 2020) on 6ix